There is increasing evidence that hepoxilins are novel inflammatory mediators. In vitro studies have shown that hepoxilins cause the mobilization of intracellular calcium in human neutrophils, induce plasma leakage, and potently stimulate the chemotaxis of human neutrophils. In vivo, the hepoxilin pathway is activated in conditions with inflammation, for example, pathogen infection, psoriasis, and arthritis, and hepoxilins promote inflammatory hyperalgesia and allodynia.
All fatty acid hydroperoxides readily give rise to epoxyalcohol derivatives, although strictly speaking, only derivatives of the arachidonic acid hydroperoxide 12S-hydroperoxyeicosatetraenoic acid (12S-HPETE) merit the designation of "hepoxilin." Nonetheless, all the others are regarded as hepoxilin-related or hepoxilin-type fatty acid derivatives. 2 In addition, a genetic defect linked to a deficiency in hepoxilin formation has been described and is believed to be responsible for the scaly skin observed in ichthyosis. 1 Mutations in the coding regions of ALOX12B, which encodes 12R-lipoxygenase (ALOX12), and ALOXE3, which encodes lipoxygenase-3 (ALOXE3),
have been reported in patients with autosomal recessive congenital ichthyosis. 3 Pathogenic mechanisms of ichthyosis arising from ALOX12B and ALOXE3 mutations are now thought to be the deficient oxidation of linoleic acids of EOS ceramides and the malformation of the corneocyte lipid envelope. 4 In addition, both enzymes convert arachidonic acids to the corresponding hepoxilin-like epoxyalcohols, 8R-hydroxy-11R and 12R-epoxyeicosatrienoic acid, via 12R-HPETE. 5 This sequence has been hypothesized to be a part of a novel lipoxygenase (LOX) pathway in skin that plays an important role in terminal differentiation. 5 Thus, the hepoxilins play an important role not only in inflammation but also in the regulation of proliferation and differentiation of epithelial cells, especially keratinocytes.
Psoriasis is a common skin disorder that is characterized by hyperkeratosis, epidermal hyperplasia, T-cell and neutrophil recruitment, and changes in the vascular endothelial system. 6, 7 The etiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious, and lifestyle factors. 8, 9 The manner in which genetic and environmental factors interact to contribute to the molecular disease mechanisms has remained elusive. 8 Upregulation of several variable lipid mediators, including the eicosanoids, in psoriatic keratinocytes was described previously, although some results were contradictory. 7 Since hepoxilin is less stable than other eicosanoids such as hydroxyeicosatetraenoic acid (HETE), the measurement of hepoxilin is difficult. In this study, to clarify the relationship between hepoxilin/hepoxilin-related fatty acid derivatives and the development of psoriatic skin, we determined the amount of production of lipid mediators including hepoxilins in plaque lesions of patients with psoriasis vulgaris (PV) and psoriatic arthritis (PsA) compared to normal controls.
| ME THODS

| Human skin tissues
Patients with PV and PsA were enrolled at the outpatient clinic of the Department of Dermatology, Nagoya University Hospital. 
Abbreviations: HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; KETE, keto-eicosatetraenoic acid. Data are displayed as medians (minimum-maximum). Boldface indicates statistically significant results. a FDR was calculated by Benjamini-Hochberg adjustment.
*P values were calculated by Wilcoxon rank-sum test.
TA B L E 2 Comparison of each hepoxilin and its related lipids between patients with psoriasis and normal controls
Electrospray ionization was performed in the negative ion mode with a temperature of 400°C. The ion spray voltage was set at −4500 V. respectively, set at −80 and −20 for the quantification of hepoxilin B 3 and at −110 and −18 for the quantification of the other analytes.
| Determination of epidermal concentrations of eicosanoid metabolites
Ethanol 
| Statistical analysis
Variables are expressed as medians (range) or n (%), and they were compared between patients and normal controls using the Wilcoxon rank-sum test and Fisher's exact test. All P-values were two-tailed. A P-value of <0.05 was considered statistically significant. When the production of a lipid mediator was not detected, its amount was set as 0. Lipid mediators that were detected in at least one sample were subjected to further analysis. The amount of production of each lipid mediator was compared between patients and normal controls using the Wilcoxon rank-sum test. P-values for lipid mediators that were detected in at least one sample were adjusted for false discovery rate (FDR) based on the Benjamini and Hochberg method to correct for multiple testing. An FDR value of <0.05 was considered to be statistically significant. All statistical analyses were conducted using SAS 9.4 (SAS Institute, Inc., Cary, NC, USA). Abbreviations: HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; KETE, keto-eicosatetraenoic acid. Data are displayed as medians (minimum -maximum). a FDR was calculated by Benjamini-Hochberg adjustment.
TA B L E 4 Comparison of each hepoxilin and its related lipids between patients with psoriasis and psoriatic arthritis
| RE SULTS
| Hepoxilin and its related lipids in psoriatic skin
First, we measured the content of hepoxilin B3, hepoxilin A3,
12-HPETE, 12-HETE, 12-keto-eicosatetraenoic acid (KETE), and
trioxilin B3 in the skin specimens collected from the PPG and 10 normal controls. In the PPG, all hepoxilins and their related lipids were more abundant than in the normal controls (Table 2) . Among these lipids, we could not detect (below the limit of quantification) hepoxilin A3 or 12-HPETE in the PPG or the control group, and trioxilin B3-2(S) was only detected in the PPG (Table 2 ).
| Each isomer of hepoxilin and HETE in psoriatic skin
Next, all of the hepoxilin and HETE contained in the skin samples were separated for each isomer, and the amount of each isomer was measured. In the PPG, most of the isomers of hepoxilin and HETE were more abundant than those in controls. As for 12R-HETE, the PPG had significantly higher amounts than those of the controls. The ratio of 12R-HETE/12S-HETE differed between the PPG and the normal controls (PPG: 2.47 (0.39-8.86); controls: 0 (0-0.09)). The amount of 12S-HETE did not significantly differ between the PPG and the controls. Thus, the production of 12R-HETE was specifically increased in the PPG (Table 2 ).
TA B L E 5 Comparison of each lipid mediator of patients between psoriasis and psoriatic arthritis
| Each lipid mediator in psoriatic skin
To ascertain which pathway is important in the development of psoriatic skin, the amount of each metabolic product in arachidonic acid and eicosapentaenoic acid (EPA) systems contained in the skin samples from the PPG and the controls was measured. Median values for each lipid in skin tissues from the PPG and the controls are described in Table 3 . Lipids produced in the LOX pathway were more abundant in the skin tissue from PPG than in the skin from controls, whereas the lipids produced by COX pathway tended to be less abundant in the psoriatic skin.
| Comparison of lipid production between psoriatic arthritis and psoriasis vulgaris (psoriasis without arthritis)
Furthermore, we compared the amounts of each lipid between
PsA patients and PV patients (Tables 4 and 5 ). Within this analysis, prostaglandins (PGs) E 1 , E 2 , and E 3 extracted from lesional skin samples were more abundant for the PsA patients than for the PV patients, although statistical significance was not obtained. No significant difference was present between the two study groups in any hepoxilin derivatives or lipid mediators.
| D ISCUSS I ON
To the best of our knowledge, no reports have given a comprehensive analysis of lipid mediators in psoriatic skin lesions. Most of the hepoxilins and their related lipids that were evaluated in this study tended to be more abundant in the lesional skin of the PPG than in skin from the controls (Tables 2 and 3 ). Hepoxilins are classified into type A and type B.
2 Because of the differences in chemical stability,
Comparisons of the amount of each hepoxilin-related lipid, each isomer of hepoxilin and HETE between psoriatic skin and normal skin, and of the amount of prostaglandin E 1 , E 2 , and E 3 in lesional skins between patients with psoriatic arthritis and those with psoriasis without arthritis. A, Box plot for the amount of each hepoxilin-related lipid extracted from the lesional skin samples of patients with psoriasis and normal control skins. B, Box plot for the amount of each isomer of hepoxilin and HETE extracted from the lesional skin samples of patients with psoriasis and normal control skins. *Significant difference (P < 0.05, Wilcoxon rank-sum test)
hepoxilin B3 is commonly detected in tissue extracts, whereas the hepoxilin A3 may appear as the corresponding hydrolysis product, trioxilin A3. 2 In the literature, the level of hepoxilin B3 was greatly increased in the lesional scales in psoriasis, along with the corresponding trioxilin B3. 11, 12 Our results are consistent with these findings. However, the previous report used extracts from scales (not skin samples from biopsy) and used the different methods (gas chromatography-mass spectrometry). These studies were performed at least two decades earlier, and the clinical features of psoriasis and the number of patients were not included in the previous report.
11
Interestingly, 12R-HETE was markedly increased in the skin samples of the PPG. This result is consistent with lipid analyses in previous reports. 7 The first indication of a role for oxidized polyunsaturated fatty acids in skin biology came in the mid-1970s, when an accumulation of 12-HETE and free arachidonic acid was discovered in psoriatic epidermis. 2 A decade later, 12-HETE in psoriatic skin lesions was shown to be mainly 12R-HETE. 2 The synthesis of 12R-HETE in psoriasis had been thought to be induced by inflammation in the epidermis. Yet 12R-HETE itself showed only modest proinflammatory activity. From a current perspective, the abundance of 12R-HETE in psoriasis may merely reflect the production of free F I G U R E 2 Spectra of metabolic pathways to and from arachidonic acids (eicosanoids). A, A comprehensive schematic of the arachidonic acid metabolic cascade. B, Detailed pathways and enzymes in the area marked with the red dotted line in (A). 12-HPETE produced via ALOX12 pathway is converted by ALOXE3 to hepoxilin A3 and hepoxilin B3, which are further metabolized to the corresponding trioxillions. Abbreviations: COX, cyclooxygenase; diHOME, dihydrometabolites; HDoHE, hydroxydocosahexaenoic acid; HETE, hydroxyeicosatetraenoic acid; HETrE, hydroxyeicosatrienoic acid; HODE, hydroxyoctadecadienoic acid; Hx, hepoxilin; LOX, lipoxygenase; LT, leukotriene; PG, prostaglandin; TX, thromboxane antagonists are known, and their clinical evaluation is ongoing. 13 In vivo, SC53228, an LTB 4 antagonist, inhibits LTB 4 -induced skin inflammation in guinea pigs and counteracts inflammation induced by 12R-HETE. 13 The compound has been selected for clinical trials for a number of diseases including psoriasis, 13 although no clinical benefit has been reported.
In the present study, the lipids produced in the LOX pathway, including hepoxilin, were more abundant in the skin lesions for the PPG than in the skin of the normal controls. In contrast, the lipids produced by the COX pathway were decreased in the skin lesions of the PPG ( Figure 1B and Table 3 ). From these results, the LOX pathway was more predominant than the COX pathway in the lesional skin of the PPG. Therefore, our results suggest that an imbalance between LOX and COX pathways may contribute to the pathomechanisms of psoriasis.
None of our results correlated with the PASI scores for the PPG in the present study (data not shown). The absence of correlation might be due to the fact that the severity of the psoriatic changes and the levels of inflammation at the skin biopsy sites were not directly associated with the PASI scores of the patients. In addition, various treatments which the patients had might have affected both the PASI and the levels of lipid mediators.
The clinical course of psoriasis may be complicated by the concomitant joint disease PsA in 7%-40% of patients. 14 The relationship between skin and joint manifestations is not clear. 15 Although early diagnosis may lead to early treatment and benefits for PsA patients, the reliable prediction of PsA development in PV patients has not been established. 16 Recently, a group for the research and assessment of psoriasis and psoriatic arthritis proposed serum biomarkers including interleukin-6, matrix metalloproteinase-3, and others as markers to distinguish PsA from PV. 15, 17 In the present study, interestingly, PGE 1 and PGE 3 were more highly expressed in the skin samples from PsA than in those from PV. Different from PGE 2 , PGE 1 has anti-inflammatory effects on endothelial cells and certain subsets of leukocytes. 18 In addition, PGE 3 may have antiproliferative and anti-inflammatory activities. 19 In contrast, F I G U R E 3 Spectra of metabolic pathways to and from eicosapentaenoic acids. Abbreviations: COX, cyclooxygenase; diHOME, dihydrometabolites; HDHA, hydroxy docosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HpETE, hydroperoxyeicosatetraenoic acid; LOX, lipoxygenase; LT, leukotriene; PG, prostaglandin; TX, thromboxane in the case of rheumatoid arthritis, PGE 2 has been found in the synovial fluid and the roles of PGE 2 in inflammation was emphasized. 20 Perhaps the inflammation in the affected joints of patients with PsA might correlate with the production of PGE 1 and PGE 3 ( Figures 2 and 3 ).
To ascertain whether there are any molecular differences between the psoriasis plaque lesions from PsA patients and those from PV patients, we analyzed the difference in amounts of each lipid in the two groups (Table 5 ). In the present study, no significant differences were found in the levels of hepoxilin derivatives and lipid mediators between the two groups, although the small sample size of our study for this analysis was a limitation of the present study.
The further accumulation of samples from psoriasis cases with and without PsA is needed to confirm the molecular role of PGs in PsA.
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